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coverage is compromised in the region of PlanSMPCM 
(yellow).  
Table 1: Comparison of VMAT S-IMRT and Do-IMRT plan dose-
volume statistics for PlanPTVs (edited 5mm from body 
surface and excluding PlanPTV_6500 from PlanPTV_5400), 
spinal cord, brainstem, contralateral (CL) and ipsilateral (IL) 
parotids, PlanSMPCM and PlanIPCM. 
 
 
 
Conclusion: Do-IMRT can be achieved using VMAT for the 
DARS trial. Fixed-field IMRT may also be used to reduce 
constrictor dose, however is unlikely to produce plans 
acceptable within the DARS trial QA guidelines. 
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Purpose or Objective: RT plan rejections are defects that 
cause suboptimal or erroneous treatments if undetected and 
should be a focus of improvement. Applying the DMAIIC 
(Define, Measure, Analyze, Improve, Implement, and Control) 
formalism to clinic workflow provides actionable parameters 
for feedback and process correction. In our clinic, a web-
based treatment planning board shows the real-time 
workflow and compiles causes of plan rejection, which can 
be categorized and quantified for subsequent process 
improvement efforts. 
 
Material and Methods: Data was collected from July 2014-
September 2015. 341 (of 673) entries associated with plan 
rejection were categorized as changes in one of the 
following: (1) tumor anatomy/patient setup; (2) 
dose/volume; (3) tumor/OAR constraints; (4) treatment 
planning modification generated during plan review; and (5) 
external (patient-, disease-, or hospital/equipment-
generated) causes. Each entry was initiated by the physician, 
physicist, or dosimetrist involved in planning. Analyzed time 
intervals included the following: (1) dosimetry contours; (2) 
MD contour approval; (3) dosimetry plan computed; (4) 
physics plan precheck; (5) MD plan approval; and (6) total 
time for planning from simulation/planning board entry until 
MD plan approval (TMD). The data was analyzed with Two-
way ANOVA, Student T-test, and Pearson correlation. 
 
Results: The mean TMD time was 85 hrs (+/- 45). With 
breakdown by interval, the mean dosimetry contour (16 hrs), 
MD contour approval (27 hrs), dosimetry planning (12 hrs), 
physics precheck (4 hrs), and MD approval (11 hrs) times were 
calculated. The planning modification category was a 
significant source of variation in planning time (p<0.0001). 
Treatment planning modifications presented the predominant 
(50%) source of planning delay, followed by constraint (26%), 
dose/volume (18%), external (4%), and tumor 
anatomy/patient setup changes (2%). Those with tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest TMD, dosimetry contour, dosimetry plan 
computing, and MD plan approval intervals. 27% of plan 
modifications were initiated by physicians, 70% by physicists, 
and 3% by dosimetrists. Entries initiated by physicians on the 
planning board were associated with shorter TMD times than 
when physicists initiated plan rejection (p=0.016). 
 
Conclusion: We report a novel process for quantification of 
clinical RT plan rejections. In this analysis, tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest treatment TMD times. Physician-initiated plan 
modification entries were associated with shorter TMD times, 
which may denote early, proactive involvement—an optimal 
approach with complicated or aggressive disease. Though 
planning delays may depend on department infrastructure 
and patient population, our method provides a 
comprehensive census to optimize planning throughput and 
can be applied as a part of broader process improvement. 
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Purpose or Objective: Craniospinal irradiation is performed 
rarely in a palliative intention due to concerns of acute 
toxicities (mostly dysphaghia and bone marrow supression). 
Therefore the purpose of this study was to evaluate the 
dosimetric parameters responsible for the acute toxicity in 
patients with leptomeningeal metastasis of a solid cancer 
treated with craniospinal irradiation (CSI) by helical 
tomotherapy (HT), 3D conformal radiotherapy (3D-CRT) and 
Protons. 
 
Material and Methods: Data of five adult patients previously 
treated with HT CSI were evaluated. For each patient the 
initial tomotherapy plan (inHT) was compared to a 3D 
conformal plan (3D-CRT), a scanning proton beam plan (p-
CSI) as well as to a specifically optimized bone marrow (BM) 
sparing tomotherapy plan (BM-HT). The BM-HT was also 
optimized to reduce the acute dysphagia. The prescribed 
dose was 36 Gy. All active bone marrow compartments were 
delineated separately according to Campbell et al. To 
analyse the impact of different bone marrow compartments 
weighted bone marrow exposure (WBME) was used. 
WBME Dmean =Σ(proportion (%) of functional bone marrow 
according to anatomical site x Dmean to anatomical site)  
WBME V20=Σ(proportion (%) of functional bone marrow 
according to anatomical site x V20 to anatomical site)  
This calculation was also performed for V30. 
Further, the following organ at risks (OARs) were delineated: 
left and right submandibular glands, the parotid glands, the 
eyes, the cochlea, the oral cavity, the pharynx, the thyroid 
gland, the esophagus, the heart, both lungs, both kidneys, 
the liver, the bowel, and the pancreas. For all of these 
structures the Dmean in all four treatment plans were 
analyzed. 
Descriptive statistics were used to analyze the results. 
 
Results: p-CSI results in the best sparing of the organs at risk 
(OARs) including the active bone marrow compartments. BM-
HT achieved better results as inHT and 3D-CRT regarding 
bone marrow sparing (see Figure 1.). Dose to the crucial OARs 
responsible for dysphagia was also reduced with BM-HT. The 
trade off for this was an slightly increased lung and kidney 
dose. 
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Figure 1. Total bone marrow and weighted bone marrow 
dosimetry (presented are averages and 95% confidence 
intervals). 
 
Conclusion: With the use of the novel techniques such as p-
CSI and BM-HT quality of life impairing acute side effects 
such as cytopenias and dysphagia can be reduced. We 
propose WBME to better assess the impact on active bone 
marrow. 
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Purpose or Objective: Whole lung irradiation (WLI) of 12 to 
18 Gy is used as treatment for lung metastases in patients 
with Ewing sarcoma and Wilms tumour. This results in 
irradiation of normal tissues including heart and breast. 
Conventionally this treatment has been delivered with 
standard AP-PA fields. To minimise cardiac radiation dose 
and reduce the risk of subsequent late complications, we 
validated the use of VMAT to deliver WLI without increasing 
the predicted risks of secondary breast cancers compared to 
AP-PA fields. 
 
Material and Methods: Five female patient datasets (ages 
ranging from 3 to 18 years) were used for this retrospective 
study. The planning target volume (PTV) included total lung 
volume with a 1 cm margin (and adjacent vertebrae for three 
patients). Organs at risks included were heart, breast 
bud/tissue, liver and thyroid. 6 MV AP-PA (with segments) 
and RapidArc (2 or 3 full arcs) plans were created using the 
Eclipse treatment planning system (Version 11). Plans were 
calculated using the anisotropic analytical algorithm (AAA). 
The prescribed dose was either 15 Gy in 10 fractions or 18 Gy 
in 12 fractions based on the patient’s age. PTV D2%, D98% 
and D50% and mean and maximum doses for heart and breast 
were obtained. The absolute excess risk (AER) of cardiac 
mortality at 15 years post treatment was calculated for each 
plan based on an age-at-exposure adjusted relative risk per 
Gy obtained from published data (1,2,3,4) combined with 
contemporary UK population-based absolute risks. The risk of 
breast cancer induction was calculated using the model 
proposed by Schneider et al. (2011) (5). 
 
Results: The VMAT plans resulted in a similar minimum PTV 
coverage when compared to the AP-PA plans whilst reducing 
the PTV D2% by an average of 6.1% (4.1 – 9.1). The use of 
VMAT reduced the heart and breast mean dose by an average 
of 19.1% (11.7 – 30.5) and 16.2% (-2.2 – 30.4) respectively 
when compared to the AP-PA plans. The difference in AER of 
cardiac mortality at 15 years was lower for the VMAT plans by 
an average of 0.48% (0.11 – 0.98). The average excess 
absolute risk (EAR) for breast cancer induction across all 
plans decreased by 2.9% (-0.8 – 6.8) when compared to the 
conformal plans (assuming α/β = 3 Gy, α = 0.067 Gy-1, R = 
0.62, µ = 4.8/10000PY/Gy). 
 
 
Conclusion: VMAT achieved highly conformal plans and 
reduced cardiac late normal tissue complication probability 
whilst also reducing (or achieving similar) predicted risk of 
second cancer induction in breast tissue. 
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Purpose or Objective: Traditionally, patients with rectal 
cancer (T2 anterior low rectum, T3-T4 N0-N+) are treated 
with preoperative radiotherapy or chemoradiation (CAP 50 
regimen). 3D Conformal Radiation Therapy is conventionally 
delivered: 44 Gy more 6 Gy as a sequential boost to the high 
risk target volume (total dose 50 Gy). Another strategy would 
be to use the Contact Therapy technique [1] using 50 kV X-
rays (CXRT) to deliver higher dose (30 Gy) to the high risk 
target volume in addition to 44 Gy. The present study first 
describes CXRT dose computation with Monte-Carlo 
simulations and then compares the resulting dose 
(EBRT+CXRT) with the conventional treatment (EBRT only). 
 
Material and Methods: The CXRT machine Papillon 50™ 
installed in Centre Antoine Lacassagne (Nice, France) delivers 
a 50 kV X-ray beam with a dose rate close to 15 Gy/min, 
allowing treatment delivery more comfortable for the 
patients [2]. The system is currently used for treating skin 
and rectal cancers. The detailed geometry of the Papillon 
50™ machine [3] was fully generated in Monte-Carlo code 
PenEasy based on PENELOPE [4] and the resulting simulations 
were validated against measurements in water (depth dose 
curves and transverse dose profiles) for all applicators used 
for rectum cancer. For 10 patients with T2-T3 nodes smaller 
than 3 cm, dose distributions were calculated to irradiate the 
high risk target volume. For each patient, 30 Gy CXRT dose 
was computed with Monte-Carlo simulation in 3DCT patient 
data acquired in a position close to the rectal cancer CXRT 
position (genupectoral position). 6 Gy EBRT treatment was 
computed with the commercial TPS Isogray (Dosisoft) in the 
3DCT scan acquired in supine position. Both dose 
distributions were compared in terms of dosimetric indices 
computed for target volumes (conformity and homogeneity 
indices) and dose to organs at risk. 
 
Results: Monte-Carlo penEasy simulations are in good 
agreement with the Papillon50TM measurements in water for 
